All In Biotech

Drug Trial Radar · NCT07116694

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Jun 19, 2025

Primary completion

Oct 7, 2025

Study completion Oct 7, 2025

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Premier Research
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.

Conditions

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorders
  • Psychomotor Agitation

Interventions

  • BXCL501 Sublingual FilmDrug

    Single dose BXCL501 120 mcg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Informant and Clinician ratings comparisonTime frame: Before and 2 hours after the intervention
  2. Informant training materials assessmentTime frame: Within 7 days of the intervention

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site 103

    Chino, California

  • BioXcel Clinical Research Site 105

    Oceanside, California

  • BioXcel Clinical Research Site 102

    Orange, California

  • BioXcel Clinical Research Site 101

    St Louis, Missouri

  • BioXcel Clinical Research Site 106

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.